Best Practice & Research Clinical Rheumatology
Volume 21, Issue 4 , Pages 601-628 , August 2007

Quantitative measures of rheumatic diseases for clinical research versus standard clinical care: differences, advantages and limitations

  • Theodore Pincus, MD (Director of Outcomes Research)

      Affiliations

    • Corresponding Author InformationCorresponding author. NYU Hospital for Joint Diseases, 301 East 17 Street, New York, NY 10003, USA. Tel.: +1 615-936-2152; Fax: +1 615-936-2159.

References 

  1. Goldsmith CH, Smythe HA, Helewa A. Interpretation and power of pooled index. Journal of Rheumatology. 1993;20:575–578
  2. van Riel PLCM. Provisional guidelines for measuring disease activity in clinical trials on rheumatoid arthritis (Editorial). British Journal of Rheumatology. 1992;31:793–794
  3. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis and Rheumatism. 1993;36:729–740
  4. Tugwell P, Boers M, OMERACT Committee . Proceedings of the OMERACT Conferences on outcome measures in rheumatoid arthritis clinical trials. Journal of Rheumatology. 20. Netherlands: Maastrict; 1993;527–591
  5. van der Heijde DMFM, van't Hof M, van Riel PLCM, van de Putte LBA. Development of a disease activity score based on judgment in clinical practice by rheumatologists. Journal of Rheumatology. 1993;20:579–581
  6. Prevoo MLL, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts: Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis and Rheumatism. 1995;38:44–48
  7. Petri M, Hellmann DB, Hochberg M. Validity and reliability of lupus activity measures in the routine clinic setting. Journal of Rheumatology. 1992;19:53–59
  8. Bencivelli W, Vitali C, Isenberg DA, et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. III. Development of a computerised clinical chart and its application to the comparison of different indices of disease activity. The European Consensus Study Group for Disease Activity in SLE. Clinical and Experimental Rheumatology. 1992;10(5):549–554
  9. Hawker G, Gabriel S, Bombardier C, et al. A reliability study of SLEDAI: a disease activity index for systemic lupus erythematosus. Journal of Rheumatology. 1993;20:657–660
  10. Hay EM, Bacon PA, Gordon C, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. The Quarterly Journal of Medicine. 1993;86(7):447–458
  11. Gladman DD, Urowitz MB, Goldsmith CH, et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis and Rheumatism. 1997;40(5):809–813
  12. Mosca M, Bencivelli W, Vitali C, et al. The validity of the ECLAM index for the retrospective evaluation of disease activity in systemic lupus erythematosus. Lupus. 2000;9(6):445–450
  13. Swaak AJ, van den Brink HG, Smeenk RJ, et al. Systemic lupus erythematosus. Disease outcome in patients with a disease duration of at least 10 years: second evaluation. Lupus. 2001;10(1):51–58
  14. Lam GKW, Petri M. Assessment of systemic lupus erythematosus. Clinical and Experimental Rheumatology. 2005;23:S120–S132
  15. Luqmani RA, Bacon PA, Moots RJ, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. The Quarterly Journal of Medicine. 1994;87:671–678
  16. Bacon PA, Moots RJ, Exley E, et al. VITAL assessment of vasculitis - Workshop report. Clinical and Experimental Rheumatology. 1995;13:275–278
  17. Exley AR, Bacon PA, Luqmani RA, et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis and Rheumatism. 1997;40:371–380
  18. Whiting O'Keefe QE, Stone JH, Hellmann DB. Validity of a vasculitis activity index for systemic necrotizing vasculitis. Arthritis and Rheumatism. 1999;42:2365–2371
  19. Stone JH, Hoffman GS, Merkel PA, et al. A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. Arthritis and Rheumatism. 2001;44:912–920
  20. Seo P, Min Y, Holbrook JT, et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trail (WGET). Arthritis and Rheumatism. 2005;52:2168–2178
  21. Clegg DO, Reda DJ, Weisman MH, et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis and Rheumatism. 1996;39(12):2004–2012
  22. Fleischer JAB, Feldman SR, Rapp SR, et al. Disease severity measures in a population of psoriasis patients: the symptoms of psoriasis correlate with self-administered psoriasis area severity index scores. Journal of Investigative Dermatology. 1996;107:26–29
  23. Kavanaugh A, Cassell S. The assessment of disease activity and outcomes in psoriatic arthritis. Clinical and Experimental Rheumatology. 2005;23:S142–S147
  24. Dougados M, Gueguen A, Nakache JP, et al. Evaluation of a functional index and an articular index in ankylosing spondylitis. Journal of Rheumatology. 1988;15:302–307
  25. Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. Journal of Rheumatology. 1994;21(12):2281–2285
  26. Calin A, Nakache JP, Gueguen A, et al. Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument?. Rheumatology (Oxford). 1999;38(9):878–882
  27. Calin A, MacKay K, Santos H, Brophy S. A new dimension to outcome: application of the Bath Ankylosing Spondylitis Radiology Index. Journal of Rheumatology. 1999;26(4):988–992
  28. Zochling J, Braun J. Assessment of ankylosing spondylitis. Clinical and Experimental Rheumatology. 2005;23:S133–S141
  29. Pincus T. Laboratory tests in rheumatic disorders. In:  Klippel JH,  Dieppe PA editor. Rheumatology. London: Mosby International; 1997;p. 10.1–10.8
  30. Pincus T. A pragmatic approach to cost-effective use of laboratory tests and imaging procedures in patients with musculoskeletal symptoms. Primary Care. 1993;20:795–814
  31. Tugwell P, Bombardier C. A methodologic framework for developing and selecting endpoints in clinical trials. Journal of Rheumatology. 1982;9:758–762
  32. Bombardier C, Tugwell P. A methodological framework to develop and select indices for clinical trials: statistical and judgmental approaches. Journal of Rheumatology. 1982;9:753–757
  33. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis and Rheumatism. 1980;23:137–145
  34. Pincus T, Swearingen C, Wolfe F. Toward a multidimensional health assessment questionnaire (MDHAQ): Assessment of advanced activities of daily living and psychological status in the patient friendly health assessment questionnaire format. Arthritis and Rheumatism. 1999;42:2220–2230
  35. Pincus T, Sokka T, Kautiainen H. Further development of a physical function scale on a multidimensional health assessment questionnaire for standard care of patients with rheumatic diseases. Journal of Rheumatology. 2005;32:1432–1439
  36. Pincus T, Strand V, Koch G, et al. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the disease activity score (DAS) in a rheumatoid arthritis clinical trial. Arthritis and Rheumatism. 2003;48(3):625–630
  37. Pincus T, Amara I, Koch GG. Continuous indices of Core Data Set measures in rheumatoid arthritis clinical trials: lower responses to placebo than seen with categorical responses with the American College of Rheumatology 20% criteria. Arthritis and Rheumatism. 2005;52:1031–1036
  38. Wolfe F, Michaud K, Pincus T. A composite disease activity scale for clinical practice, observational studies and clinical trials: the patient activity scale (PAS/PAS-II). Journal of Rheumatology. 2005;32:2410–2415
  39. Pincus T, Sokka T. Quantitative measures for assessing rheumatoid arthritis in clinical trials and clinical care. Best Practice and Research. Clinical Rheumatology. 2003;17:753–781
  40. Pincus T, Sokka T. Quantitative measures and indices to assess rheumatoid arthritis in clinical trials and clinical care. Rheumatic Diseases Clinics of North America. 2004;30:725–751
  41. Pincus T, Sokka T. Complexities in the quantitative assessment of patients with rheumatic diseases in clinical trials and clinical care. Clinical and Experimental Rheumatology. 2005;23:S1–S9
  42. Pincus T. Advantages and limitations of quantitative measures to assess rheumatoid arthritis: joint counts, radiographs, laboratory tests, and patient questionnaires. Bulletin of the Hospital for Joint Diseases. 2006;64:32–39
  43. Pincus T, Sokka T. Quantitative measures to assess patients with rheumatic diseases: 2006 update. Rheumatic Disease Clinical Updates. 2006;1:1–9
  44. Cooperating Clinics Committee of the American Rheumatism Association . A seven-day variability study of 499 patients with peripheral rheumatoid arthritis. Arthritis and Rheumatism. 1965;8:302–335
  45. Ritchie DM, Boyle JA, McInnes JM, et al. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. The Quarterly Journal of Medicine. 1968;New Series 37:393–406
  46. American Rheumatism Association . Dictionary of the rheumatic diseases vol. I: signs and symptoms. New York: Contact Associates International; 1982;
  47. Decker JL. American Rheumatism Association nomenclature and classification of arthritis and rheumatism. Arthritis and Rheumatism. 1983;26:1029–1032
  48. Fuchs HA, Callahan LF, Kaye JJ, et al. Radiographic and joint count findings of the hand in rheumatoid arthritis: Related and unrelated findings. Arthritis and Rheumatism. 1988;31:44–51
  49. Egger MJ, Huth DA, Ward JR, et al. Reduced joint count indices in the evaluation of rheumatoid arthritis. Arthritis and Rheumatism. 1985;28:613–619
  50. Sokka T, Pincus T. Quantitative joint assessment in rheumatoid arthritis. Clinical and Experimental Rheumatology. 2005;23:S58–S62
  51. Mason JH, Anderson JJ, Meenan RF, et al. The Rapid Assessment of Disease Activity in Rheumatology (RADAR) questionnaire: validity and sensitivity to change of a patient self-report measure of joint count and clinical status. Arthritis and Rheumatism. 1992;35:156–162
  52. Stucki G, Liang MH, Stucki S, et al. A self-administered rheumatoid arthritis disease activity index (RADAI) for epidemiologic research. Arthritis and Rheumatism. 1995;38:795–798
  53. Escalante A. What do self-administered joint counts tell us about patients with rheumatoid arthritis?. Arthritis Care and Research. 1998;11:280–290
  54. Houssien DA, Stucki G, Scott DL. A patient-derived disease activity score can substitute for a physician-derived disease activity score in clinical research. Rheumatology. 1999;38:48–52
  55. Taal E, Abdel-Nasser AM, Rasker JJ, Wiegman O. A self-report Thompson articular index: what does it measure?. Clinical Rheumatology. 1998;17:125–129
  56. Hanly JG, Mosher D, Sutton E, et al. Self-assessment of disease activity by patients with rheumatoid arthritis. Journal of Rheumatology. 1996;23:1531–1538
  57. Prevoo MLL, Kuper IH, van Leeuwen M, et al. Validity and reproducibility of self-administered joint counts. A prospective longitudinal followup study in patients with rheumatoid arthritis. Journal of Rheumatology. 1996;23:841–845
  58. Voon E, Phan L, Ruttkay D, et al. Patient self-administered joint tenderness and swelling counts in RA are reliable and responsive to therapy. Arthritis and Rheumatism. 1997;40:S286
  59. Hewlett SE, Haynes J, Shepstone L, Kirwan JR. Rheumatoid arthritis patients cannot accurately report signs of inflammatory activity. British Journal of Rheumatology. 1995;34:547–553
  60. Stewart MW, Palmer DG, Knight RG, Highton J. A self-report articular index: relationship to variations in mood and disease activity measures. British Journal of Rheumatology. 1993;32:631–632
  61. Wolfe F. Comparative usefulness of c-reactive protein and erythrocyte sedimentation rate in patients with rheumatoid arthritis. Journal of Rheumatology. 1997;24:1477–1485
  62. Pincus T. The DAS is the most specific measure, but a patient questionnaire is the most informative measure to assess rheumatoid arthritis. Journal of Rheumatology. 2006;33:834–837
  63. Bombardier C, Tugwell P, Sinclair A, et al. Preference for endpoint measures in clinical trials: results of structured workshops. Journal of Rheumatology. 1982;9:798–801
  64. Wolfe F, Pincus T, Thompson AK, Doyle J. The assessment of rheumatoid arthritis and the acceptability of self-report questionnaires in clinical practice. Arthritis Care and Research. 2003;49(1):59–63
  65. Lewis PA, O'Sullivan MM, Rumfeld WR, et al. Significant changes in Ritchie scores. British Journal of Rheumatology. 1988;27:32–36
  66. Hart LE, Tugwell P, Buchanan WW, et al. Grading of tenderness as a source of interrater error in the Ritchie articular index. Journal of Rheumatology. 1985;12:716–717
  67. Thompson PW, Hart LE, Goldsmith CH, et al. Comparison of four articular indices for use in clinical trials in rheumatoid arthritis: patient, order and observer variation. Journal of Rheumatology. 1991;18:661–665
  68. Klinkhoff AV, Bellamy N, Bombardier C, et al. An experiment in reducing interobserver variability of the examination for joint tenderness. Journal of Rheumatology. 1988;15:492–494
  69. Scott DL, Choy EHS, Greeves A, et al. Standardising joint assessment in rheumatoid arthritis. Clinical Rheumatology. 1996;15:579–582
  70. Tugwell P, Wells G, Strand V, et al. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: Sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Leflunomide rheumatoid arthritis investigators group. Arthritis and Rheumatism. 2000;43:506–514
  71. Scott DL, Grindulis KA, Struthers GR, et al. Progression of radiological changes in rheumatoid arthritis. Annals of Rheumatic Diseases. 1984;43:8–17
  72. Pincus T, Callahan LF, Sale WG, et al. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis and Rheumatism. 1984;27:864–872
  73. Hawley DJ, Wolfe F. Sensitivity to change of the Health Assessment Questionnaire (HAQ) and other clinical and health status measures in rheumatoid arthritis: results of short term clinical trials and observational studies versus long term observational studies. Arthritis Care and Research. 1992;5:130–136
  74. Sharp JT, Wolfe F, Mitchell DM, Bloch DA. The progression of erosion and joint space narrowing scores in rheumatoid arthritis during the first twenty-five years of disease. Arthritis and Rheumatism. 1991;34:660–668
  75. Egsmose C, Lund B, Borg G, et al. Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. Journal of Rheumatology. 1995;22:2208–2213
  76. Fex E, Jonsson K, Johnson U, Eberhardt K. Development of radiographic damage during the first 5-6 yr of rheumatoid arthritis. A prospective follow-up study of a Swedish cohort. British Journal of Rheumatology. 1996;35:1106–1115
  77. Mulherin D, Fitzgerald O, Bresnihan B. Clinical improvement and radiological deterioration in rheumatoid arthritis: Evidence that pathogenesis of synovial inflammation and articular erosion may differ. British Journal of Rheumatology. 1996;35:1263–1268
  78. Leirisalo-Repo M, Paimela L, Peltomaa R, et al. Functional and radiological outcome in patients with early RA - A longitudinal observational study. Arthritis and Rheumatism. 1999;42:S130
  79. Graudal N, Tarp U, Jurik AG, et al. Inflammatory patterns in rheumatoid arthritis estimated by the number of swollen and tender joints, the erythrocyte sedimentation rate, and hemoglobin: Longterm course and association to radiographic progression. Journal of Rheumatology. 2000;27:47–57
  80. Welsing PMJ, van Gestel AM, Swinkels HL, et al. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis and Rheumatism. 2001;44(9):2009–2017
  81. Puolakka K, Kautiainen H, Mottonen T, et al. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis and Rheumatism. 2005;52:36–41
  82. Puolakka K, Kautiainen H, Mottonen T, et al. Predictors of productivity loss in early rheumatoid arthritis: a 5 year follow up study. Annals of Rheumatic Diseases. 2005;64:130–133
  83. Pincus T. The case for early intervention in rheumatoid arthritis. Journal of Autoimmunity. 1992;5(Suppl A):209–226
  84. Pincus T, Callahan LF. The ‘side effects’; of rheumatoid arthritis: Joint destruction, disability and early mortality. British Journal of Rheumatology. 1993;32(Suppl 1):28–37
  85. Emery P, Salmon M. Early rheumatoid arthritis: time to aim for remission?. Annals of Rheumatic Diseases. 1995;54:944–947
  86. Weinblatt ME. Rheumatoid arthritis: Treat now, not later! (editorial). Annals of Internal Medicine. 1996;124:773–774
  87. Pincus T, Gibofsky A, Weinblatt ME. Urgent care and tight control of rheumatoid arthritis as in diabetes and hypertension: better treatments but a shortage of rheumatologists. Arthritis and Rheumatism. 2002;46(4):851–854
  88. Pincus T, Segurado OG. Most visits of most patients with rheumatoid arthritis to most rheumatologists do not include a formal quantitative joint count. Annals of Rheumatic Diseases. 2006;65:820–822
  89. Larsen A. A radiological method for grading the severity of rheumatoid arthritis, Academic dissertation, University of Helsinki. Helsinki: 1974.
  90. Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiologica: Diagnosis (Stockholm). 1977;18:481–491
  91. Sharp JT, Lidsky MD, Collins LC, Moreland J. Methods of scoring the progression of radiologic changes in rheumatoid arthritis: correlation of radiologic, clinical and laboratory abnormalities. Arthritis and Rheumatism. 1971;14:706–720
  92. Sharp JT. Scoring radiographic abnormalities in rheumatoid arthritis. Journal of Rheumatology. 1989;16:568–569
  93. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. Journal of Rheumatology. 1999;26:743–745
  94. Landewe R, van der Heijde D. Radiographic progression in rheumatoid arthritis. Clinical and Experimental Rheumatology. 2005;23:S63–S68
  95. Rau R, Wassenberg S, Herborn G, et al. A new method of scoring radiographic change in rheumatoid arthritis. Journal of Rheumatology. 1998;25:2094–2107
  96. Pincus T, Larsen A, Brooks RH, et al. Comparison of 3 quantitative measures of hand radiographs in patients with rheumatoid arthritis: Steinbrocker Stage, Kaye Modified Sharp Score, and Larsen Score. Journal of Rheumatology. 1997;24:2106–2112
  97. Nance EP, Kaye JJ, Callahan LF, et al. Observer variation in quantitative assessment of rheumatoid arthritis: part I. Scoring erosions and joint space narrowing. Investigations in Radiology. 1986;21:922–927
  98. Kaye JJ, Nance EP, Callahan LF, et al. Observer variation in quantitative assessment of rheumatoid arthritis: part II. A simplified scoring system. Investigations in Radiology. 1987;22:41–46
  99. Kaye JJ, Callahan LF, Nance EP, et al. Bony ankylosis in rheumatoid arthritis: Associations with longer duration and greater severity of disease. Investigations in Radiology. 1987;22:303–309
  100. Genant HK. Methods of assessing radiographic change in rheumatoid arthritis. The American Journal of Medicine. 1983;75(Suppl 6A):35–47
  101. van der Heijde DMFM, van Leeuwen MA, van Riel PLCM, et al. Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis and Rheumatism. 1992;35:26–34
  102. Larsen A. How to apply Larsen score in evaluating radiographs of rheumatoid arthritis in longterm studies?. Journal of Rheumatology. 1995;22:1974–1975
  103. Kaarela K, Kautiainen H. Continuous progression of radiological destruction in seropositive rheumatoid arthritis. Journal of Rheumatology. 1997;24:1285–1287
  104. Rau R, Herborn G. A modified version of Larsen's scoring method to assess radiologic changes in rheumatoid arthritis. Journal of Rheumatology. 1995;22:1976–1982
  105. Rau R, Wassenberg S, Herborn G, et al. Identification of radiologic healing phenomena in patients with rheumatoid arthritis. Journal of Rheumatology. 2001;28(12):2608–2615
  106. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. The Journal of the American Medical Association. 1949;140:659–662
  107. Sharp JT. Radiological Assessment of Joint Damage: The Premier Outcome Measure in Rheumatoid Arthritis. Current Status and Future Potential. In:  Wolfe F,  Pincus T editor. Rheumatoid Arthritis: Pathogenesis, Assessment, Outcome, and Treatment. New York: Marcel Dekker, Inc; 1994;p. 167–189
  108. Pincus T, Callahan LF, Brooks RH, et al. Self-report questionnaire scores in rheumatoid arthritis compared with traditional physical, radiographic, and laboratory measures. Annals of Internal Medicine. 1989;110:259–266
  109. Sokka T, Kankainen A, Hannonen P. Scores for functional disability in patients with rheumatoid arthritis are correlated at higher levels with pain scores than with radiographic scores. Arthritis and Rheumatism. 2000;43:386–389
  110. Pincus T, Callahan LF. What is the natural history of rheumatoid arthritis?. Rheumatic Diseases Clinics of North America. 1993;19:123–151
  111. Wakefield RJ, Kong KO, Conaghan PG, et al. The role of ultrasonography and magnetic resonance imaging in early rheumatoid arthritis. Clinical and Experimental Rheumatology. 2003;21:S42–S49
  112. Klarlund M, Ostergaard M, Jensen KE, et al. Magnetic resonance imaging, radiography, and scintigraphy of the finger joints: one year follow up of patients with early arthritis. The TIRA Group 3. Annals of Rheumatic Diseases. 2000;59(7):521–528
  113. Pincus T, Brooks RH, Callahan LF. Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. Annals of Internal Medicine. 1994;120:26–34
  114. Rose HM, Ragan C, Pearce E, Lipman MO. Differential agglutination of normal and sensitized sheep erythrocytes by sera of patients with rheumatoid arthritis. Proceedings of the Society for Experimental Biology and Medicine. 1948;68:1–6
  115. Westergren A. Studies of the suspension stability of the blood in pulmonary tuberculosis. Acta Medica Scandinavica. 1920;54:247–282
  116. Mallya RK, de Beer FC, Berry H, et al. Correlation of clinical parameters of disease activity in rheumatoid arthritis with serum concentration of C-reactive protein and erythrocyte sedimentation rate. Journal of Rheumatology. 1982;9:224–228
  117. Singer JM, Plotz CM. The latex fixation test: I. application to the serologic diagnosis of rheumatoid arthritis. The American Journal of Medicine. 1956;21:888–892
  118. Engel GL. The need for a new medical model: a challenge for biomedicine. Science. 1977;196:129–136
  119. Sokka T, Pincus T. Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or American College of Rheumatology criteria for remission. Journal of Rheumatology. 2003;30(6):1138–1146
  120. Pinals RS, Masi AT, Larsen RA, et al. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis and Rheumatism. 1981;24:1308–1315
  121. Riedemann JP, Muñoz S, Kavanaugh A. The use of second generation anti-CCP antibody (anti-CCP2) testing in rheumatoid arthritis – a systematic review. Clinical and Experimental Rheumatology. 2005;23:S69–S76
  122. Wolfe F, Michaud K. The clinical and research significance of the erythrocyte sedimentation rate. Journal of Rheumatology. 1994;21:1227–1237
  123. Pincus T, Sokka T. Prevalence of normal erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) on presentation of patients with rheumatoid arthritis (RA) at two rheumatology settings, one in the US and the other in Finland: Is a patient questionnaire a better quantitative measure of clinical severity?. Arthritis and Rheumatism. 2005;52(9):S127
  124. Wolfe F, Pincus T. The level of inflammation in rheumatoid arthritis is determined early and remains stable over the longterm course of the illness. Journal of Rheumatology. 2001;28(8):1817–1824
  125. Aletaha D, Smolen J. The simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clinical and Experimental Rheumatology. 2005;23:S100–S108
  126. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis and Rheumatism. 2004;50:709–715
  127. Lichtenstein MJ, Pincus T. How useful are combinations of blood tests in ‘rheumatic panels’ in diagnosis of rheumatic diseases?. Journal of General Internal Medicine. 1988;3:435–442
  128. Munves EF, Schur PH. Antibodies to Sm and RNP: prognosticators of disease involvement. Arthritis and Rheumatism. 1983;26:848–853
  129. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Medical Care. 1992;30:473–481
  130. Hurst NP, Jobanputra P, Hunter M, et al. Validity of Euroqol-a generic health status instrument-in patients with rheumatoid arthritis. British Journal of Rheumatology. 1994;33:655–662
  131. Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain. 1975;1:277–299
  132. Melzack R. The short-form McGill Pain Questionnaire. Pain. 1987;30:191–197
  133. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Archives of Neurology. 1989;46:1121–1123
  134. Tugwell P, Bombardier C, Buchanan WW, et al. The MACTAR patient preference disability questionnaire - an individualized functional priority approach for assessing improvement in physical disability in clinical trials in rheumatoid arthritis. Journal of Rheumatology. 1987;14:446–451
  135. Clinch J, Tugwell P, Wells G, Shea B. Individualized functional priority approach to the assessment of health related quality of life in rheumatology. Journal of Rheumatology. 2001;28(2):445–451
  136. Bellamy N, Buchanan WW, Goldsmith CH, et al. Validation study of WOMAC: A health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. Journal of Rheumatology. 1988;15:1833–1840
  137. Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: development and validation. Journal of Rheumatology. 1991;18:728–733
  138. Fries JF, Bruce B, Cella D. The promise of PROMIS: using item response theory to improve assessment of patient-reported outcomes. Clinical and Experimental Rheumatology. 2005;23:S53–S57
  139. Pincus T, Wolfe F. An infrastructure of patient questionnaires at each rheumatology visit: Improving efficiency and documenting care. Journal of Rheumatology. 2000;27:2727–2730
  140. Wolfe F, Pincus T. Listening to the patient: A practical guide to self-report questionnaires in clinical care. Arthritis and Rheumatism. 1999;42:1797–1808
  141. Pincus T, Wolfe F. Patient questionnaires for clinical research and improved standard patient care: is it better to have 80% of the information in 100% of patients or 100% of the information in 5% of patients?. Journal of Rheumatology. 2005;32:575–577
  142. Bergmann FJ, Chassany O, Gandiol J, et al. A randomised clinical trial of the effect of informed consent on the analgesic activity of placebo and naproxen in cancer pain. Clinical Trials and Meta-analysis. 1994;29:41–47
  143. Pincus T, Yazici Y, Bergman M. Saving time and improving care with a multidimensional health assessment questionnaire: 10 practical considerations. Journal of Rheumatology. 2006;33:448–454
  144. Wolfe F, Cathey MA. The assessment and prediction of functional disability in rheumatoid arthritis. Journal of Rheumatology. 1991;18:1298–1306
  145. Callahan LF, Bloch DA, Pincus T. Identification of work disability in rheumatoid arthritis: Physical, radiographic and laboratory variables do not add explanatory power to demographic and functional variables. Journal of Clinical Epidemiology. 1992;45:127–138
  146. Wolfe F, Hawley DJ. The longterm outcomes of rheumatoid arthritis: Work disability: A prospective 18 year study of 823 patients. Journal of Rheumatology. 1998;25:2108–2117
  147. Sokka T, Kautiainen H, Möttönen T, Hannonen P. Work disability in rheumatoid arthritis 10 years after the diagnosis. Journal of Rheumatology. 1999;26:1681–1685
  148. Lubeck DP, Spitz PW, Fries JF, et al. A multicenter study of annual health service utilization and costs in rheumatoid arthritis. Arthritis and Rheumatism. 1986;29:488–493
  149. Wolfe F, Zwillich SH. The long-term outcomes of rheumatoid arthritis: A 23-year prospective, longitudinal study of total joint replacement and its predictors in 1,600 patients with rheumatoid arthritis. Arthritis and Rheumatism. 1998;41:1072–1082
  150. Wolfe F, Kleinheksel SM, Cathey MA, et al. The clinical value of the Stanford health assessment questionnaire functional disability Index in patients with rheumatoid arthritis. Journal of Rheumatology. 1988;15:1480–1488
  151. Leigh JP, Fries JF. Mortality predictors among 263 patients with rheumatoid arthritis. Journal of Rheumatology. 1991;18:1307–1312
  152. Callahan LF, Cordray DS, Wells G, Pincus T. Formal education and five-year mortality in rheumatoid arthritis: Mediation by helplessness scale scores. Arthritis Care and Research. 1996;9:463–472
  153. Callahan LF, Pincus T, Huston JW, et al. Measures of activity and damage in rheumatoid arthritis: Depiction of changes and prediction of mortality over five years. Arthritis Care and Research. 1997;10:381–394
  154. Söderlin MK, Nieminen P, Hakala M. Functional status predicts mortality in a community based rheumatoid arthritis population. Journal of Rheumatology. 1998;25:1895–1899
  155. Sokka T, Hakkinen A, Krishnan E, Hannonen P. Similar prediction of mortality by the health assessment questionnaire in patients with rheumatoid arthritis and the general population. Annals of Rheumatic Diseases. 2004;63:494–497
  156. Russak SM, Croft JD, Furst DE, et al. The use of rheumatoid arthritis health-related quality of life patient questionnaires in clinical practice: lessons learned. Arthritis Care and Research. 2003;49:574–584
  157. Yazici Y, Kautiainen H, Sokka T. Differences in clinical status measures in different ethnic/racial groups with early rheumatoid arthritis: implications for interpretation of clinical trial data. J Rheumatol. 2007;34:311–315
  158. Pincus T. Rheumatology function tests: quantitative physical measures to monitor morbidity and predict mortality in patients with rheumatic diseases. Clinical and Experimental Rheumatology. 2005;23:S85–S89
  159. Pincus T. A 3-page standard protocol to evaluate rheumatoid arthritis (SPERA): efficient capture of essential data for clinical trials and observational studies. Clinical and Experimental Rheumatology. 2005;23:S114–S119
  160. Pincus T, Brooks RH, Callahan LF. A proposed standard protocol to evaluate rheumatoid arthritis (SPERA) that includes measures of inflammatory activity, joint damage, and longterm outcomes. Journal of Rheumatology. 1999;26:473–480
  161. Pincus T, Brooks RH, Callahan LF. Reliability of grip strength, walking time and button test performed according to a standard protocol. Journal of Rheumatology. 1991;18:997–1000
  162. Pincus T, Yazici Y, Bergman M, et al. Simplified formats of visual analog scales for use in standard rheumatology clinical care: agreement between a 10 cm horizontal line and 21 numbered circles. Arthritis and Rheumatism. 2006;54:S345–S346
  163. Pincus T. The American College of Rheumatology (ACR) core data set and derivative ‘patient only’ indices to assess rheumatoid arthritis. Clinical and Experimental Rheumatology. 2005;23:S109–S113
  164. Fransen J, van Riel PLCM. The disease activity score and the EULAR response criteria. Clinical and Experimental Rheumatology. 2005;23:S93–S99
  165. Bellamy N. The WOMAC knee and hip osteoarthritis indices: development, validation, globalization and influence on the development of the AUSCAN hand OA indices. Clinical and Experimental Rheumatology. 2005;23:S148–S153
  166. Bennett R. The fibromyalgia impact questionnaire (FIQ): a review of its development, current version, operating characteristics and uses. Clinical and Experimental Rheumatology. 2005;23:S154–S162
  167. Mukhtyar C, Hellmich B, Jayne D, et al. Remission in antineutrophil cytoplasmic antibody-associated systemic vasculitis. Clinical and Experimental Rheumatology. 2006;24(S43):S93–S98
  168. Wells GA, Boers M, Shea B, et al. Minimal disease activity for rheumatoid arthritis: a preliminary definition. Journal of Rheumatology. 2005;32:2016–2024
  169. Sharp JT. Assessment of radiographic abnormalities in rheumatoid arthritis: What have we accomplished and where should we go from here?. Journal of Rheumatology. 1995;22:1787–1791
  170. Pincus T, Chung C, Segurado OG, et al. An index of patient self-reported outcomes (PRO Index) discriminates effectively between active and control treatment in 4 clinical trials of adalimumab in rheumatoid arthritis. Journal of Rheumatology. 2006;33:2146–2152
  171. Wells G, Li T, Maxwell L, et al. Sensitivity of measures of function and patient reported outcomes following treatment with abatacept in patients with rheumatoid arthritis. Arthritis and Rheumatism. 2005;52:S467
  172. Pincus T, Bergman M, Yazici Y, et al. Rheumatoid arthritis patient index data (RAPID): performance in two abatacept clinical trials of 4 absolute indices of 2-5 core data set measures based on patient reported outcomes for use in standard clinical care. Arthritis and Rheumatism. 2006;54:S375
  173. Callahan LF, Smith WJ, Pincus T. Self-report questionnaires in five rheumatic diseases: Comparisons of health status constructs and associations with formal education level. Arthritis Care and Research. 1989;2:122–131
  174. Wolfe F, Michaud K, Pincus T. Development and validation of the health assessment questionnaire II: a revised version of the health assessment questionnaire. Arthritis and Rheumatism. 2004;50:3296–3305
  175. Creemers MC, Franssen MJ, van't Hof MA, et al. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Annals of Rheumatic Diseases. 2005;64(1):127–129
  176. Jenkinson TR, Mallorie PA, Whitelock HC , et al. Defining spinal mobility in ankylosing spondylitis (AS): the Bath AS metrology index. Journal of Rheumatology. 1994;21(9):1694–1698
  177. van der Heijde D, Klareskog L, Boers M, et al. Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Annals of Rheumatic Diseases. 2005;64(11):1582–1587
  178. Fuchs HA, Brooks RH, Callahan LF, Pincus T. A simplified twenty-eight joint quantitative articular index in rheumatoid arthritis. Arthritis and Rheumatism. 1989;32:531–537
  179. Sokka T, Pincus T. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis. Arthritis and Rheumatism. 2003;48(2):313–318
  180. Sokka T, Kautiainen H, Toloza S et al. QUEST-RA: Quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. Annals of Rheumatic Diseases, in press.

PII: S1521-6942(07)00023-X

doi: 10.1016/j.berh.2007.02.007

Best Practice & Research Clinical Rheumatology
Volume 21, Issue 4 , Pages 601-628 , August 2007

Article Tools

* Image Usage & Resolution